Forecasts

Novo Nordisk : NVO

NVO

Stock Data

$50.37

$0.19 (0.38%)

Asset Type

Common Stock

Exchange

NYSE

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

DRUG MANUFACTURERS - GENERAL

Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, Denmark.

All Novo Nordisk Articles

126 Articles

Joel South | Nov 21, 2025 at 8:25 AM EST

Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2025-2030 (Nov 2025)

Novo Nordisk sees the obesity drug market expanding to $100 billion by 2030. With promising new treatments in the pipeline,…

Douglas A. McIntyre | Nov 14, 2025 at 4:13 PM EST

Retail Investors Really Don’t Like Novo Nordisk (NVO) Stock

Shares of Novo Nordisk A/S (NYSE: NVO) dropped 1.9%today, closing at $48.25, just a whisker above the 52-week low of…

Omor Ibne Ehsan | Nov 11, 2025 at 10:07 AM EST

3 Buy-And-Forget Dividend Stocks With Snowballing Payouts

If the headline yield today is not something you’re concerned with, and you pay more attention to how fast a…

Trey Thoelcke | Nov 5, 2025 at 8:45 AM EST

Insiders Scoop Up Shares of This Biotech IPO, Energy Giant, and More

In the past week or so, a biotech and an energy infrastructure giant saw some huge insider buying. These were…

Rich Duprey | Nov 3, 2025 at 10:13 AM EST

Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that…

Rich Duprey | Oct 22, 2025 at 11:48 AM EDT

Market Meltdown Coming? These 2 ETFs Are Ready to Surge If Stocks Tank

The U.S. stock market has delivered impressive gains for over a decade, but warning signs of a potential downturn are…

Rich Duprey | Oct 17, 2025 at 11:05 AM EDT

Is Trump Going to Kill the GLP-1 Cash Cow?

The Boom That Built Billion-Dollar Empires GLP-1 drugs have reshaped the pharmaceutical landscape, turning obesity and diabetes treatments into massive…

Rich Duprey | Oct 1, 2025 at 10:47 AM EDT

100% Pharmaceutical Tariffs Are Here. Time to Buy These 3 Drugmakers

Starting today, the U.S. imposed 100% tariffs on imports of branded or patented pharmaceutical products that President Trump announced last…

Omor Ibne Ehsan | Sep 17, 2025 at 10:28 AM EDT

3 Stocks Insiders Are Buying Non-Stop

Insider buying is one of the few market signals that does not hide behind algorithms or price targets. When a…

Omor Ibne Ehsan | Sep 2, 2025 at 3:45 PM EDT

Jim Cramer Says This “Ridiculously Cheap” Healthcare Stock is a Buy

Healthcare investing has felt like walking through quicksand this year. One moment, the sector looks ready to spring forward on…

Rich Duprey | Aug 27, 2025 at 8:23 AM EDT

Eli Lilly’s Obesity Pill Breakthrough Shakes Up $150 Billion Weight-Loss Race

A Fierce Battle for Weight-Loss Supremacy The weight-loss drug market has become a battleground, ignited by the runaway success of…

Rich Duprey | Aug 22, 2025 at 12:13 PM EDT

Novo Nordisk Roars Back: 6 Catalysts Driving the Pharma’s Path to Dominance

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug market,…

Joel South | Aug 19, 2025 at 9:08 AM EDT

Stock Market Live August 19: S&P 500 (VOO) Rally Still on Hold Pending Fed Talk

This article will be updated throughout the day, so check back often for more daily updates. It’s a pretty slow…

Joel South | Aug 18, 2025 at 9:12 AM EDT

Stock Market Live August 18: S&P 500 (VOO) Rally Pauses After Inconclusive Russia Talks

This article will be updated throughout the day, so check back often for more daily updates. The S&P 500 closed…

Rich Duprey | Aug 6, 2025 at 11:35 AM EDT

There Is Only 1 GLP-1 Stock to Buy In 2025

Weighing the Options The introduction of Novo Nordisk’s (NYSE:NVO) Ozempic revolutionized the fight against obesity, shifting the narrative from lifestyle…